Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CRMD vs CAPR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CRMD Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

CRMD Overall Winner 6-Pillar Tally: CRMD 4 – 2 CAPR Matrix Metrics: CRMD 7 – 3 CAPR

As of Nov 16, 2026, CorMedix Inc. (CRMD) is the stronger overall head-to-head candidate over Capricor Therapeutics Inc (CAPR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CRMD carries a Unified Composite Score of 53.2/100 (HOLD) at $4.92 (49.0x Forward P/E, 41.0% operating margin), whereas CAPR carries 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: CRMD earns the overall head-to-head edge with a stronger Unified Composite Score (53.2/100 HOLD vs. CAPR 28.0/100 SELL) and 1.20β · 107% Vol risk profile, whereas CAPR leads top-line expansion (-7.9% YoY revenue growth, 0.38x PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: CRMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.3); meanwhile CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CRMD vs CAPR
CRMD NASDAQ Head-to-Head Winner
CorMedix Inc.
Pharmaceutical Preparations
$4.92
+5.47% 1D
Market Cap $384.7M
TTM Revenue $1.05B
Forward P/E 49.0x
Beta / 30D Vol 1.20β · 107% Vol
Unified Composite Score
53.2 / 100 HOLD
Tech 60.0 Fund 60.0 Flow 69.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.2%), weak momentum, RSI 29
RSI-14: 29.3 · SMA20: $6.32 · SMA50: $7.11
CAPR NASDAQ
Capricor Therapeutics Inc
Pharmaceutical Preparations
$8.47
-11.12% 1D
Market Cap $595.4M
TTM Revenue $11M
Forward P/E 78.7x
Beta / 30D Vol 1.52β · 152% Vol
Unified Composite Score
28.0 / 100 SELL
Tech 50.0 Fund 37.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.2% over 20 days), RSI 51
RSI-14: 51.3 · SMA20: $7.79 · SMA50: $8.08

6-Pillar Scorecard Institutional Category Breakdown (CRMD 4 – 2 CAPR)

Columns: Metric · CRMD · CAPR
1. Valuation Multiples CRMD
Forward P/E 49.0x 78.7x
Trailing P/E 2.4x 78.7x
PEG Ratio 3.79x 0.38x
EV / Revenue N/M 57.8x
2. Growth & Scale CAPR
Revenue Growth (YoY) -47.7% -7.9%
Earnings Growth (YoY) +6.7% +0.0%
TTM Revenue (USD) $1.05B $11M
Market Cap $384.7M $595.4M
3. Profitability & Quality CRMD
Gross Margin 87.4% N/A
Operating Margin 41.0% 0.0%
Net Profit Margin 15.5% 0.0%
Return on Equity (ROE) 15.3% -100.5%
4. Balance Sheet & Cash Flow CRMD
Cash Generation (TTM) $785M -$146M
Cash Flow Margin 74.6% N/A
Net Cash / Leverage $535M Net Cash $48M Net Debt (0.44x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CAPR
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 56.3% (25th %ile) 637.1% (89th %ile)
Put/Call OI Skew 0.69x (Call-Skewed) 1.57x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown ACCUMULATION · Markup
6. R&D & Supply-Chain Moat CRMD
OpEx & R&D Intensity 46.4% of Rev ($488M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CRMD (7) vs CAPR (3)
Institutional Metric CRMD CAPR Criterion Row Edge
Market Capitalization
Scale
$384.7M $595.4M Larger Scale CAPR
Trailing P/E Ratio
Valuation
2.4x 78.7x Lower Multiple CRMD
Forward P/E Ratio
Valuation
49.0x 78.7x Lower Multiple CRMD
Revenue Growth (YoY)
Growth
-47.7% -7.9% Higher Growth CAPR
Operating Margin (TTM)
Profitability
41.0% 0.0% Higher Margin CRMD
Net Profit Margin
Profitability
15.5% 0.0% Higher Margin CRMD
Return on Equity (ROE)
Capital Efficiency
15.3% -100.5% Higher ROE CRMD
52-Week Range Position
Momentum
3% ($5–$13) 15% ($3–$40) Stronger Trend CAPR
Beta / 30D Volatility
Risk Regime
1.20β · 107% Vol 1.52β · 152% Vol Lower Realized Risk CRMD
Unified Institutional Score
Composite Signal
53.2 / 100 (HOLD) 28.0 / 100 (SELL) Higher Composite CRMD
Trailing 12M Revenue (USD)
Operating Scale
$1.05B $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
87.4% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.79x PEG · N/M EV/Rev 0.38x PEG · 57.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$785M ($535M Net Cash) -$146M ($48M Net Debt (0.44x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CAPR +58.53 pp
CRMD: -32.3% · CAPR: +26.23%
3M Horizon CAPR +59.47 pp
CRMD: -39.84% · CAPR: +19.63%
6M Horizon CRMD +35.68 pp
CRMD: -34.9% · CAPR: -70.58%
1Y Horizon CAPR +102.95 pp
CRMD: -56.16% · CAPR: +46.79%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CRMD Revenue CAPR Revenue CRMD Op. Margin CAPR Op. Margin Margin Leader
FY2018 $0M $0M -6250.4% -917.0% CAPR
FY2019 $0M $0M -7416.3% -769.5% CAPR
FY2020 $0M $0M -11378.4% -4412.6% CAPR
FY2021 $0M $0M -15417.5% -8549.9% CAPR
FY2022 $0M $0M -46819.9% -1163.9% CAPR
FY2023 N/A $30M N/A -95.6% CAPR
FY2024 $40M $20M -51.4% -191.1% CRMD
FY2025 $310M N/A 48.2% N/A CRMD

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CRMD BREAKDOWN
109d in phase · OBV DISTRIBUTION
Current IV 56.3%
IV Percentile 25th %ile
Put/Call OI Skew 0.69x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact CRMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CAPR CONSOLIDATION
56d in phase · OBV ACCUMULATION
Current IV 637.1%
IV Percentile 89th %ile
Put/Call OI Skew 1.57x (Put-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CAPR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CRMD Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $384.7M market capitalization and 41.0% operating margin.
OpEx & R&D Reinvestment 46.4% of Rev ($488M)
90D Engineering Disclosures 0 Published
CAPR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $595.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CRMD vs CAPR Key Questions & Quantitative Answers

As of Nov 16, 2026, CorMedix Inc. (CRMD) is the stronger overall head-to-head candidate over Capricor Therapeutics Inc (CAPR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CRMD carries a Unified Composite Score of 53.2/100 (HOLD) at $4.92 (49.0x Forward P/E, 41.0% operating margin), whereas CAPR carries 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: CRMD earns the overall head-to-head edge with a stronger Unified Composite Score (53.2/100 HOLD vs. CAPR 28.0/100 SELL) and 1.20β · 107% Vol risk profile, whereas CAPR leads top-line expansion (-7.9% YoY revenue growth, 0.38x PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CRMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.3); meanwhile CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CAPR leads the Growth & Scale pillar: CRMD posts -47.7% YoY revenue growth and +6.7% YoY earnings growth on $1.05B TTM revenue (87.4% gross margin, 41.0% operating margin), compared with CAPR at -7.9% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CRMD cumulative revenue shifted +675.0% while CAPR shifted -33.3%. In operating R&D and SG&A reinvestment, CRMD deploys 46.4% of Rev ($488M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CAPR.

CRMD screens cheaper on headline valuation multiples. CRMD trades at 49.0x Forward P/E, 2.4x Trailing P/E, 3.79x PEG, and N/M EV/Revenue (74.6% FCF margin), whereas CAPR trades at 78.7x Forward P/E, 78.7x Trailing P/E, 0.38x PEG, and 57.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRMD (15.3% ROE) versus CAPR (-100.5% ROE) capital efficiency.

In options market volatility and institutional positioning, CRMD carries 56.3% implied volatility (25th %ile, Compressed (<25th %ile)), a 0.69x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.20β · 107% Vol realized risk). By comparison, CAPR carries 637.1% implied volatility (89th %ile, Extreme (>80th %ile)), a 1.57x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.52β · 152% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.